association
Full identifier: http://purl.org/np/RAq1A183gz-VxqBS8UZNa8Xwn-suoq3MJPYmhzvg6VRz4#association
Assigned to 1 class:
Minted in Nanopublication
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
"enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non blacks see warnings head and neck angioedema"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
has drug
https://identifiers.org/drugbank:DB00584
drugbank:DB00584
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
has disease
http://purl.obolibrary.org/obo/DOID_6000
DOID_6000
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
https://w3id.org/biolink/vocab/relation
has relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
An indication for only managing the symptoms of the condition
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
https://w3id.org/biolink/vocab/association_type
has BioLink type
https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation
ChemicalToDiseaseOrPhenotypicFeatureAssociation
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
has type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
association Statement
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
has predicate
https://w3id.org/biolink/vocab/treats
treats
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#association
This association
https://w3id.org/biolink/vocab/provided_by
is provided by
https://w3id.org/um/NeuroDKG
NeuroDKG
.
This is the identifier for the assertion of this nanopublication.
http://purl.org/np/RAq1A183gz...#assertion
The assertion above
http://www.w3.org/ns/prov#wasAttributedTo
is attributed to
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
This nanopublication
http://purl.org/dc/terms/creator
is created by
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
This nanopublication
date and time when the nanopublication was created
http://purl.org/dc/terms/created
was created on
(this is a literal)
"2021-07-03T15:56:20.105+02:00"
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
This nanopublication
links to the assertion template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
was created from the assertion template
http://purl.org/np/RAManV5GZI...
RAManV5GZI
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
This nanopublication
links to the provenance template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
was created from the provenance template
http://purl.org/np/RANwQa4ICW...
RANwQa4ICW
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
This nanopublication
links to the publication info template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
was created from the publication info template
http://purl.org/np/RAA2MfqdBC...
RAA2MfqdBC
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget
has as target
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq1A183gz...
this nanopublication
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm
has the algorithm
(this is a literal)
"RSA"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#sig
sig
http://purl.org/nanopub/x/hasPublicKey
has the public key
(this is a literal)
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq1A183gz...#sig
sig
http://purl.org/nanopub/x/hasSignature
has the signature
(this is a literal)
"WNla4f0+m0XPUpq3DhE9FcevCzXIaYoP0l8KBdcOZWJuFtCJ0KKvOITcfr/zLe2eN5WrutymMXrnraOr2cnGb5uezWJ3NnGni38pBbkta5t7wsheZG+BXsSPQVlI8bRgHk3GXPB1MZrNbS8bAY1KQiD7eX8VYjWd7yj26ms2xlE="
.
References
Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
---|---|---|---|---|---|---|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non blacks see warnings head and neck angioedema
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T13:56:20.105Z
|